Answers are grounded in this paper and cite their sources.
Introduction: Cutaneous T lymphomas (CTCL) are within the heterogeneous group of non-Hodgkin lymphomas (NHL) that do not originate in lymph nodes.The recommended treatment combines chemotherapy, radiotherapy and immunotherapy.Presentation of the case: a patient with mycosis fungoides in the tumour phase is presented, who receives treatment with anti-CD6 monoclonal antibody, itoluzumab, with good clinical response and low toxicity.Conclusions: There is evidence that relates the autoreactivity of T lymphocytes with increased expression of CD6 on their cell membrane.The murine monoclonal antibody ior®-t1 (IgG2a anti-CD6) recognizes the human CD6 molecule.This mAb recognizes human cell lines in cultures of T and B origin.The administration of the anti-CD6 mAb itolizumab is safe and reports a benefit in clinical response.
No takes yet. Share an insight, caveat, or question.
Aguirrechu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: